Cytokinetics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.9 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 118.23% +0.94pp
- Institutions
- 578 +5
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 16 buys · 34 sells
| Name | Role | Stake |
|---|---|---|
| Robert Blum | Chief Executive Officer | 0.09% |
| Fady Malik | Officer | 0.07% |
| John Henderson | Independent Chairperson | 0.06% |
| Wendell Wierenga | Independent Director | 0.03% |
| Nancy Wysenski | Independent Director | 0.02% |
| Muna Bhanji | Independent Director | 0.02% |
| Robert Harrington | Independent Director | 0.02% |
| Sung Lee | EVP & CFO | 0.01% |
| B. Parshall | Independent Director | 0.01% |
| Edward Kaye | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-08 | B. Parshall | Independent Director | Open Market Disposition | -5,000 | $54.17–55.26 |
| 2026-11-02 | Fady Malik | Officer | Derivative Exercise and Sale | -3,500 | $7.80–62.93 |
| 2026-11-01 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–62.81 |
| 2026-10-19 | Fady Malik | Officer | Derivative Exercise and Sale | -3,500 | $7.80–64.01 |
| 2026-10-15 | Wendell Wierenga | Independent Director | Other Acquisition | +97 | $63.92 |
| 2026-10-15 | Nancy Wysenski | Independent Director | Other Acquisition | +97 | $63.92 |
| 2026-10-15 | John Henderson | Independent Chairperson | Other Acquisition | +352 | $63.92 |
| 2026-10-15 | James Daly | Independent Director | Other Acquisition | +195 | $63.92 |
| 2026-10-15 | Robert Harrington | Independent Director | Other Acquisition | +195 | $63.92 |
| 2026-10-15 | Edward Kaye | Independent Director | Other Acquisition | +195 | $63.92 |
| 2026-10-11 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–62.88 |
| 2026-10-05 | Fady Malik | Officer | Derivative Exercise and Sale | -3,500 | $7.80–61.38 |
| 2026-09-27 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–65.46 |
| 2026-09-21 | Fady Malik | Officer | Derivative Exercise and Sale | -3,500 | $7.80–68.29 |
| 2026-09-14 | Robert Blum | Chief Executive Officer | Open Market Disposition | -97,926 | $69.33 |
| 2026-09-14 | Robert Landry | Independent Director | Open Market Disposition | -1,000 | $72.13 |
| 2026-09-13 | Robert Blum | Chief Executive Officer | Other Acquisition | +97,926 | -- |
| 2026-09-13 | Robert Blum | Chief Executive Officer | Other Disposition | -99,276 | -- |
| 2026-09-13 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–73.44 |
| 2026-09-10 | Robert Landry | Independent Director | Open Market Disposition | -1,000 | $74.66 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Cytokinetics discussion 0 comments